I'm LongbridgeAI, I can summarize articles.Q2 2026 saw major milestones, including positive phase III results for QTORIN rapamycin in mLM, rolling NDA submission, and a $230M capital raise. The company is well-funded for launch and pipeline expansion, with multiple rare disease programs advancing and strong physician and payer interest.Based on DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Q2 2026 saw major milestones, including positive phase III results for QTORIN rapamycin in mLM, rolling NDA submission, and a $230M capital raise. The company is well-funded for launch and pipeline expansion, with multiple rare disease programs advancing and strong physician and payer interest.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.